

Thursday 15 May 2025, 17:45-18:45 CEST

Room 1, International Congress Center Messe München, Munich, Germany

We are pleased to invite you to an interactive scientific symposium on HER2+ breast cancer, in which leading experts will discuss the current treatment landscape, how it may evolve in the near future, and how decentralised cancer care can transform the patient experience. Join us for an engaging session designed to provide practical, evidence-based insights to support your clinical decision-making.

We look forward to seeing you in Munich or via the live stream!



Dr Sara M. Tolaney
Dana-Farber
Cancer Institute, USA



Dr Javier CortésMEDSIR, USA; International Breast Cancer Center,
Pangaea Oncology, Quiron Group, Spain; IOB Madrid, Spain;
Universidad Europea de Madrid, Spain



Dr Mark VerrillNorthern Centre for
Cancer Care, UK

Welcome Dr Sara M. Tolaney (Chair) How should we navigate an evolving treatment landscape for HER2+ eBC? Dr Sara M. Tolaney

- When do we need to escalate treatment?
- When do we need to de-escalate treatment?
- How might we tailor treatment to each patient using diagnostics tools (biomarkers, MRI and PET)?

How can we improve patient outcomes in HER2+ mBC?

- Does one size fit all in 1L HER2+ mBC?
- Would T-DXd be used until disease progression in the 1L setting?
- What would be the optimal treatment sequencing?
- What are the remaining unmet needs?

How is decentralised cancer care transforming the patient experience?

- What is the key evidence supporting the implementation of decentralised cancer care with HER2-targeted therapies?
- Which patients would be suitable for treatment in a decentralised cancer care setting?
- How do patient case studies of PH FDC SC in decentralised cancer care settings highlight the effectiveness of this approach?

Dr Mark Verrill

Dr Javier Cortés

Q&A All
Close Dr Sara M. Tolaney